Human VEGF-A Monoclonal Antibody

Produktübersicht

• Artikelname: Human VEGF-A Monoclonal Antibody
• Artikelnummer: ABB-YR0135
• Hersteller Artikelnummer: YR0135
• Alternativnummer: ABB-YR0135-5MG,ABB-YR0135-1MG,ABB-YR0135-20MG
• Hersteller: ABclonal
• Kategorie: Antikörper
• Applikation: ELISA, NeA
• Immunogen: Human VEGF-A
• Alternative Synonym: VPF, VEGF, MVCD1, L-VEGF

Produktbeschreibung

Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Produkteigenschaften

• NCBI: 7422
• UniProt: P15692
• Reinheit: >95% Determined by SDS-PAGE
• Target-Kategorie: VEGF-A

Anwendungsbeschreibung

• Application Verdünnung: In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
• Anwendungsbeschreibung: Cross-Reactivity: <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay. ResearchArea: Cancer immunology